D.E. Shaw & Co
XGN icon

D.E. Shaw & Co’s Exagen XGN Stock Holding History

D.E. Shaw & Co’s Portfolio XGN Stock Details XGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$231K Buy
49,712
+15,143
+44% +$57K ﹤0.01% 4518
2026
Q1 		$104K Buy
34,569
+2,990
+9% +$11.6K ﹤0.01% 4284
2025
Q4 		$192K Buy
+31,579
New +$287K ﹤0.01% 4340

Other funds holding XGN

WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
NCNMGF
Nano-Cap New Millennium Growth Fund Staten Island, New York $130M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FCM
FourWorld Capital Management New York $110M AUM 44.07% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $15.3B AUM 40.56% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return
MBAM
Mink Brook Asset Management West Palm Beach, Florida $227M AUM 64.76% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

D.E. Shaw & Co's XGN Position: Q2 2026 in Review

D.E. Shaw & Co increased its Exagen (XGN) stake by 44% in Q2 2026, buying an estimated $57K and bringing the position to 49,712 shares worth $231K. The position accounts for ﹤0.01% of the portfolio, ranked #4518.

D.E. Shaw & Co first reported a position in XGN in Q4 2025 and has held it in 3 quarters since. 57 funds tracked by Wall St. Rank hold XGN as of Q2 2026.

  • D.E. Shaw & Co held 49,712 shares of Exagen worth $231K as of Q2 2026.
  • D.E. Shaw & Co bought 15,143 Exagen shares in Q2 2026, an estimated $57K.
  • Exagen made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q2 2026, its #4518 holding.
  • D.E. Shaw & Co first reported a position in Exagen in Q4 2025 and has held it in 3 quarters since.
  • 57 funds tracked by Wall St. Rank held Exagen as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.